Risk-adaptive volumetric modulated arc therapy using biological objective functions for subvolume boosting in radiotherapy by Hardcastle, Nicholas G & Tome, Wolfgang
University of Wollongong 
Research Online 
Faculty of Engineering and Information 
Sciences - Papers: Part A 
Faculty of Engineering and Information 
Sciences 
1-1-2012 
Risk-adaptive volumetric modulated arc therapy using biological objective 
functions for subvolume boosting in radiotherapy 
Nicholas G. Hardcastle 
University of Wollongong, nhardc@uow.edu.au 
Wolfgang Tome 
University of Wollongong, wtome@uow.edu.au 
Follow this and additional works at: https://ro.uow.edu.au/eispapers 
 Part of the Engineering Commons, and the Science and Technology Studies Commons 
Recommended Citation 
Hardcastle, Nicholas G. and Tome, Wolfgang, "Risk-adaptive volumetric modulated arc therapy using 
biological objective functions for subvolume boosting in radiotherapy" (2012). Faculty of Engineering and 
Information Sciences - Papers: Part A. 2060. 
https://ro.uow.edu.au/eispapers/2060 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Risk-adaptive volumetric modulated arc therapy using biological objective 
functions for subvolume boosting in radiotherapy 
Abstract 
Simultaneous integrated boost (SIB) for prostate cancer allows increases in tumor control probability 
while respecting normal tissue dose constraints. Biological optimization functions that optimize based on 
treatment outcome can be used to create SIB prostate plans. This study investigates the feasibility of 
biologically optimized volumetric modulated arc therapy (VMAT) for SIB prostate radiotherapy. Methods. 
Five prostate cancer patients with diffusion-weighted MR images were selected for analysis. A two-step 
VMAT optimization was performed, which consisted of an initial biological optimization of a static gantry 
angle delivery followed by conversion of the static delivery to a single arc VMAT plan. A dosimetric 
analysis was performed on the resulting plans. Results. The VMAT plans resulted in a ΔEUD between the 
prostate and the boost volume of between 15.1Gy and 20.3Gy. Rectal volumes receiving 75.6Gy ranged 
from 4.5 to 9.9%. Expected rectal normal tissue complication probabilities were between 8.6% and 21.4%. 
Maximum bladder doses ranged from 73.6Gy to 75.8Gy. Estimated treatment time was 120 s or less. 
Conclusions. The presented biological optimization method resulted in deliverable VMAT plans that 
achieved sufficient modulation for SIB without violating rectal and bladder dose constraints. Advances in 
knowledge. This study presents a method for creating simultaneous integrated boost VMAT treatments 
using biological outcome objective functions. 
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Objectives. Simultaneous integrated boost (SIB) for prostate cancer allows increases in tumor control probability while respecting
normal tissue dose constraints. Biological optimization functions that optimize based on treatment outcome can be used to create
SIB prostate plans. This study investigates the feasibility of biologically optimized volumetric modulated arc therapy (VMAT) for
SIB prostate radiotherapy. Methods. Five prostate cancer patients with diffusion-weighted MR images were selected for analysis. A
two-step VMAT optimization was performed, which consisted of an initial biological optimization of a static gantry angle delivery
followed by conversion of the static delivery to a single arc VMAT plan. A dosimetric analysis was performed on the resulting plans.
Results. The VMAT plans resulted in a ΔEUD between the prostate and the boost volume of between 15.1 Gy and 20.3 Gy. Rectal
volumes receiving 75.6 Gy ranged from 4.5 to 9.9%. Expected rectal normal tissue complication probabilities were between 8.6%
and 21.4%. Maximum bladder doses ranged from 73.6 Gy to 75.8 Gy. Estimated treatment time was 120 s or less. Conclusions. The
presented biological optimization method resulted in deliverable VMAT plans that achieved sufficient modulation for SIB without
violating rectal and bladder dose constraints. Advances in knowledge. This study presents a method for creating simultaneous
integrated boost VMAT treatments using biological outcome objective functions.
1. Introduction
The benefit of a simultaneous integrated boost (SIB) for
prostate cancer is that it allows one to increase the expected
tumor control probability (TCP) while at the same time
respecting normal tissue dose constraints, compared to
the whole prostate dose escalation for plans delivering the
same equivalent uniform dose (EUD) to the entire prostate
[1, 2]. When delivering an SIB for prostate cancer, biological
objective functions for optimization of dose distributions, as
opposed to physical dose objective functions can be utilized.
That is, direct optimization of biological outcomes can be
performed. Using this technique, it has been shown that, for
prostate cancer, SIB can be delivered to a subvolume within
the prostate while adhering to normal tissue constraints.
[1, 3] SIB techniques allow one to take advantage of
advanced imaging techniques to selectively boost the dose
to a subvolume of the treatment target that may not be
controlled with standard doses and hence require a dose
higher than the minimal peripheral prescription dose to be
delivered to them to achieve adequate local control.
SIB delivery requires increased modulation of the dose
so as to achieve the desired boosting level while maintaining
a sufficient dose gradient outside of the target to minimize
the dose to surrounding healthy tissues. Kim and Tomé have
shown that static gantry angle IMRT can achieve the required
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modulation [1, 3–5]. In recent years, volumetric modulated
arc therapy (VMAT) has become an attractive method to
efficiently deliver modulated dose distributions. VMAT has
been shown to result in equivalent dose distributions in
prostate cancer in shorter delivery times when compared
with static gantry angle intensity modulated radiation ther-
apy (IMRT) [6–8]. Biological optimization of VMAT plans
for prostate cancer has also been investigated [6, 9]. The
vast majority of these studies have concentrated on prostate
only or prostate plus seminal vesicles as the target volume.
It can be argued that achievement of sufficient modulation
in these cases is more accessible than for more complex
treatment geometries. Jolly et al. [10] have provided a robust
planning strategy for an SIB technique with VMAT, treating
to three dose levels including the prostate and seminal
vesicles according to the Conventional or Hypofractionated
High-Dose Intensity-Modulated Radiotherapy for Prostate
Cancer (CHHiP) protocol [11]. The volume receiving the
highest dose under the CHHiP protocol, however, is the full
prostate plus a 5 mm margin, so the complexity of these
targets is limited. The present study extends the investigation
of VMAT for SIB to a more complex geometry, by using a
risk-adaptive VMAT optimization method, where the boost
volume is a subvolume of the prostate.
2. Methods and Materials
Five patients were selected for analysis. These included two
patients using rectal balloons and three patients without
rectal balloons. All the patients received a planning kVCT
scan as well as a T2 contrast-enhanced magnetic resonance
(MR) image. The prostate was contoured as the CTV, which
was expanded by 7 mm to obtain the PTV. A biopsy-
confirmed subvolume of enhanced contrast uptake on the
diffusion weighted imaging (DWI) MR was outlined as the
high-risk CTV. The high-risk CTV plus 8 mm was subtracted
from the PTV to obtain the residual PTV, PTV-R. A 5 mm
expansion was applied to the high-risk CTV to obtain the
high-risk PTV, PTV-H. This process resulted in no overlap
between PTV-R and PTV-H. The rectal wall was outlined
on the patients with rectal balloon, and the full rectum
was outlined on the patients with no rectal balloon. The
bladder and femoral heads were also outlined. An avoidance
structure was outlined, which consisted of a 5 cm wide ring
around the PTV plus 2 cm.
All planning was performed with the Pinnacle radiother-
apy planning system using the SmartArc VMAT optimization
algorithm (v9.100, Philips Radiation Oncology Systems,
Fitchburg, WI, USA). A set of research optimization objec-
tives, built into the Pinnacle RTPS as a plugin, that optimize
directly on TCP and NTCP were used. The plugin and
objective function have been described in detail elsewhere
[3]. Briefly, the objective function maximizes the TCP for
target volumes while minimizing the NTCP for organs at risk
(OARs). The objective function takes the form of
UTCP = TCP(1−NTCP). (1)
The TCP and NTCP calculations utilize phenomeno-
logical logistic dose response functions that are evaluated
Table 1: Biological objective functions and parameters.
ROI Objective Dose m γ
PTV NTCP 95 0.11 —
PTV-H TCP 84.5 — 8
PTV-R TCP 64.5 — 8
Rectum NTCP 76.9 0.13 —
Rectum NTCP 55.9 0.15 —
Normal NTCP 55 0.13 —
on a voxel-by-voxel basis. That is, the TCP and NTCP are
calculated for each voxel, where each voxel has its own
value of D50 and γ50 (for TCP) and D50 and m (for NTCP)
based on the physiological makeup of the tumor. D50 is
the dose that yields a tumor control probability or normal
tissue complication probability of 50% for TCP and NTCP
respectively, and γ50 and m are parameters describing the
slope of the dose response curve at the 50% probability
point for TCP and NTCP, respectively. TCP and NTCP are
calculated on a voxel-by-voxel basis so as to be able to
account for subtumor variations in the dose response curves
for tumor control and normal tissue complication. In this
study, the tumor is divided into two subvolumes requiring
separate parameters to describe their dose response curve,
and normal structures are approximated as one subvolume.
The reader is referred to Kim and Tomé for details and
derivation of the TCP and NTCP functions. [3]
A two-step process was used for optimization. In the first
step, a set of 15 beams were distributed every 24◦ around
the patient. These were selected to mimic the positions of
the initial fluence maps used in the SmartArc optimization
process. Intensity modulation of the ideal fluence was
then performed using the biological optimization function
described above. The optimization objectives for each organ
and target are given in Table 1. TCP objectives were used
on the PTV-H and the PTV-R. In addition to these TCP
objectives on the target, an NTCP objective was used on
the original PTV to limit the PTV dose to less than 100 Gy.
Two NTCP objectives were used on the rectum. The first
used the values of D50 and m representing grade 2 or higher
rectal bleeding from the QUANTEC study [12]. Since the
QUANTEC values are related to grade 2 or higher rectal
bleeding these tended to penalize only the high dose region
of the rectum. Therefore, a second NTCP objective function
was used to reduce the mid-low doses, the values of which
were taken from the NTCP parameter fitting by Tucker et al.
[13]. We note that although these values were derived also
for grade 2 or higher rectal bleeding, the parameter values
penalize mid-low doses thus were used as a surrogate for
rectal toxicities related to mid-low doses.
The optimization was run until the objective value was
reduced below a given value, typically 5–10 iterations. The
second step of the optimization involved creating a single
arc VMAT plan using the SmartArc optimization tool and
an Elekta Infinity linear accelerator with the X MLC for
delivery (Elekta North America, Atlanta, GA, USA). A 360◦
arc was selected, with a collimator angle of 30◦ and dose
















Figure 1: Isodose lines for the five patients. PTV-H is the green colorwash, PTV-R is the red colorwash and the rectum is the yellow
colorwash. P1 and P2 each had a rectal balloon; P3, P4, and P5 had no balloon.
rate set to be discretely variable from 0 to 300 MU/min. The
final gantry spacing was 4◦, and the maximum delivery time
was 120 seconds. Physical dose optimization objectives were
created based on the ideal dose distribution derived from
the biological optimization. Two steps of 40 iterations were
performed. Dose calculation based on a 2 × 2 × 2 mm3
dose grid was then performed using the adaptive convolution
dose algorithm. The rationale for the two-step optimization
process was to allow the optimizer to create an “ideal” set
of fluence maps, which would adhere to the optimization
objectives as close as possible, before using this “ideal”
dose distribution as the basis for the deliverable SmartArc
optimization. That is, the initial biological optimization
allows one to obtain the highest boost dose possible to
the subtumor volume without violating the normal tissue
constraints on the normal tissue volumes.
The plans were the transferred to Computational Envi-
ronment for Radiotherapy Research (CERR, University of
Washington in St. Louis) for analysis [14]. For all plans,
the following metrics were calculated: EUD of the PTV-H
and PTV-R and the difference between these values ΔEUD,
percentage volume of the rectum receiving 25 Gy, 50 Gy, and
70 Gy, the rectal NTCP (calculated using the QUANTEC
values for ≥ grade 2 rectal bleeding of D50 = 76.9 Gy, m =
0.13, and n = 0.09), the bladder volume receiving 55 Gy, and
the maximum bladder dose. The maximum bladder dose was
taken as the dose 1 cc of the bladder receiving the highest
dose. EUD was calculated using Equation 8 in [15] with an
SF2 of 0.48.
In addition to the plan quality analysis, one treatment
plan was selected for delivery quality assurance on an Elekta
Infinity linear accelerator. The treatment plan for patient 3
was calculated on a kVCT of the Delta4 phantom (Scandidos,
Uppsala, Sweden). The plan was delivered and the dose was
measured in the phantom. Comparison of the delivered dose
with the planned dose was performed using the 2D gamma
metric with 3%/3 mm criteria.
3. Results
The dose distributions and metrics were compared for the
five patients. Figure 1 shows the isodose lines for the five

































































































































Figure 2: DVHs for the five patients. The bladder line is dashed.





EUD (Gy) EUD (Gy) V50 Gy (%) V70 Gy (%) V75.6 Gy (%) NTCP (%) V55 Gy (%) Max (Gy)
P1 92.8 72.9 19.9 17.2 8.7 5.2 11.1 7.4 78.7
P2 92.2 72.5 19.7 26.5 7.5 3.2 8.2 11.8 74.5
P3 93.3 72.9 20.3 15.3 7.5 3.8 9.9 26.0 74.9
P4 94.8 74.2 20.6 22.8 11.0 6.2 20.0 17.5 75.6
P5 88.3 73.1 15.2 25.4 12.3 6.3 13.0 23.0 74.1
patients, showing that sufficient modulation was achieved
with one arc to conform the boost dose to the PTV-H volume
with limited coverage of the rectal volume with the boost
dose. Figure 2 shows the DVHs for the five patients for both
the PTVs and the OARs.
The dosimetric metrics are presented in Table 2. The
PTV-H targets received EUDs of between 88.34 Gy and
94.75 Gy; however, these had an upper dosimetric limit
placed on them during optimization, without which dose
volume histograms (DVHs) would exceed 100 Gy. Subtumor
boosting allowed an increase in EUD to the high-risk PTV
of between 15.22 Gy and 20.55 Gy over the dose the PTV-R
received.
The rectal DVH values for all patients met the V50 Gy
< 30% objective presented by Mohan et al. for the 2.5 Gy
× 28 fractions regime [16]. Due to the increased doses
per fraction used in this planning study, the maximum
rectal dose objective of 74 Gy used by Mohan et al. was not
considered [16]. Instead, the volumes receiving 75.6 Gy were
analysed as per the 86.4 Gy treatment regime reported by
Zelefsky et al. [17]. All patients easily met this treatment
objective of V75.6 Gy < 30%, with the maximum being 6.3%
(patient 5). The rectal NTCP values for ≥grade 2 rectal
bleeding range from 8.2% to 20.0%. The bladder DVH values
all met the V55 Gy < 30% specified by Mohan et al. [16].
There was no discernible dosimetric difference between the



































































































































Figure 3: VMAT delivery QA for patient 3. (a) shows the axial distribution obtained by delivering a risk adaptive VMAT plan to the Delta4
phantom. (b) shows the respective distributions for the dose deviation, distance to agreement, and gamma index found for this plan.
two patients with balloons and the three patients without
balloons.
The measured dose in the Delta4 phantom was compared
with the planned dose for the treatment plan selected for
delivery. Using a gamma criteria of 3%/3 mm, 95.9% of all
points passed (cf. Figure 3(b)).
4. Discussion
The capability of VMAT for achieving sufficient modulation
for prostate radiotherapy with simultaneous integrated boost
has been investigated in this study. Despite the more complex
target geometry, one treatment arc was sufficient to meet
treatment objectives. This allows one to take advantage of
advanced imaging techniques such as MRI and PET to
identify subregions in the heterogeneous tumor environment
and efficiently escalate the dose to selected volumes. It should
be noted that this technique could potentially be applied
to other treatment sites where simultaneous integrated
boosting could be advantageous. %
Despite the large differences in the rectal anatomy
between patients with a rectal balloon and patients without
a rectal balloon, there was very little difference in the
planned rectal dose between patients with and without a
rectal balloon. However, due to the high doses delivered to
the PTV-H volume, which is often in the posterior lobe of
the prostate, adjacent to the rectum, any small changes in
prostate or rectal position, size or shape could lead to large
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differences between the planned and delivered doses. As a
result, use of a rectal balloon would be beneficial due to the
improved setup reproducibility and consistency of the rectal
size and shape provided by the use of a rectal balloon.
Although contoured, the bladder and femoral head
structures were not used for optimization due to their having
very little impact on the optimization result. That is to
say, optimization on these structures was not required to
obtain the low bladder and femoral head doses observed
here. This is likely a consequence of the combination of
delivery technique, where the dose is delivered from all angles
which spreads out the dose distribution, minimizing the dose
delivered to each critical structure, and the optimization
using the normal structure, which has the effect of steepening
the dose gradient outside of the target volume.
The prostate dose in the presented plans was limited
by treating the PTV-H and PTV-R as target volumes but
the whole PTV as a normal tissue structure. This is akin to
the method for optimizing target dose based on the EUD
function presented by Wu et al. [18], who treated the target
volume as both a target and a normal tissue structure to
improve the homogeneity of the dose distribution. The result
of our target optimization method was that the dose to
the PTV-H was boosted to an EUD of 88–95 Gy whilst still
maintaining an EUD between 72.5 Gy and 74.2 Gy to the
PTV-R. This limits the dose to the urethra and rectum to
doses less than that allowed in the MSKCCC dose escalation
trial. [17] Our current method differs from that presented
by Kim and Tomé [3], who did not limit the dose on the
prostate and as such observed a more heterogeneous target
dose. The dose to the normal structures using the VMAT
technique was less than that achieved by Kim and Tomé [3]
who used a static gantry angle IMRT technique. The current
method also used two NTCP objectives on the rectum (as
opposed to one in Kim and Tomé [3]) to reduce the rectal
volumes receiving both high and mid-low doses. This is also
a contributing factor to the reduced rectal doses observed in
the current study.
5. Conclusions
We have shown that biologically optimized VMAT plans
can be derived from a risk-adaptive subtumor dose esca-
lation strategy for prostate cancer. A single arc provides
sufficient modulation to achieve dose escalation to a high-
risk subvolume of the prostate of up to a ΔEUD of 20.3 Gy
above the gEUD of the remainder of the prostate. This was
achieved without violating rectal NTCP constraints, allowing
for efficient delivery of risk-adaptive prostate radiotherapy.
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